Immunogenicity and safety of IXIARO® (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age von Kaltenböck, A, Dubischar-Kastner, K, Schuller, E, Datla, Mahima, Klade, C.S, Kishore, T.S.A

Volltext

Cross-genotype-reactivity of the immunodominant HCV CD8 T-cell epitope NS3-1073 von Fytili, P, Dalekos, G.N, Schlaphoff, V, Suneetha, P.V, Sarrazin, C, Zauner, W, Zachou, K, Berg, T, Manns, M.P, Klade, C.S, Cornberg, M, Wedemeyer, H

Volltext

Hepatitis C virus-specific T cell responses against conserved regions in recovered patients von Klade, C.S, Kubitschke, A, Stauber, R.E, Meyer, M.F, Zinke, S, Wiegand, J, Zauner, W, Aslan, N, Lehmann, M, Cornberg, M, Manns, M.P, Reisner, P, Wedemeyer, H

Volltext

[605] THERAPEUTIC PEPTIDE VACCINATION AGAINST CHRONIC HEPATITIS C VIRUS INFECTION von Klade, C.S, Wedemeyer, H, Sarrazin, C, Firbas, C, Jilma, B, Tauber, E

Volltext

445 Function and phenotype of peptide-vaccine induced HCV specific CD8+ T cells vs. acute and chronic hepatitis C von Schlaphoff, V., Jelovcan, S.B., Wiegand, J., Cornberg, M., Jilma, B., Manns, M.P., Wedemeyer, H., Klade, C.S.

Volltext

588 Optimization of schedule, route and adjuvant of therapeutic peptide vaccines against HCV von Klade, C.S., Firbas, C., Bürger, V., Zauner, W., Lingnau, K., Tauber, E., Jilma, B.

Volltext